Researchers Awarded 2026 Albany Prize

Dr. Dennis Slamon and Dr. Tony Hunter received the award for their pioneering contributions to cancer biology.

Updated on Oct. 6, 2026 in Cancer

Live Poll

Should the government prioritize funding for medical research that translates laboratory discoveries into clinical treatments?

Dr. Dennis Slamon and Dr. Tony Hunter have been awarded the 2026 Albany Prize for discoveries that revealed molecular mechanisms driving cancer. The prestigious honor includes a $500,000 cash award.

Why it matters

The award recognizes fundamental research into molecular mechanisms that has led to transformative treatments for cancer patients. This work highlights how identifying genetic triggers can change the standard of care for millions worldwide.

Slamon’s research led to the FDA approval of Herceptin in 1998, a drug now used by approximately 3.5 million women globally. HER2-positive breast cancer accounts for roughly 20% of cases, compared to 65-70% for hormone receptor-positive cancers.

The players

Dennis Slamon

He is a medical researcher at the UCLA Health Jonsson Comprehensive Cancer Center who led the development of Herceptin.

Tony Hunter

He is a scientist affiliated with the Salk Institute for Biological Studies and a co-recipient of the 2026 Albany Prize.

The details

Dr. Dennis Slamon, based at the UCLA Health Jonsson Comprehensive Cancer Center, led the first human clinical trials of Herceptin. His work involved identifying multiple HER2 gene copies in breast cancer cells and utilizing antibodies to target the resulting proteins on the cell surface.

1998: The FDA approved Herceptin for clinical use.
2026: Dr. Dennis Slamon and Dr. Tony Hunter were awarded the Albany Prize.

Health Landscape

The award underscores the shift toward targeted molecular therapies that rely on precise identification of protein markers in cancer cells. This recognition follows the success of treatments like Herceptin, which paved the way for modern precision medicine.

Patients with HER2-positive breast cancer benefit directly from the foundational research recognized by this award, which standardized the use of targeted antibody therapies. This approach allows for treatment plans tailored to the specific genetic makeup of a tumor.

The takeaway

The recognition of these researchers emphasizes the vital impact of long-term investment in basic biological science. Understanding the molecular drivers of cancer remains the most effective pathway to developing lifesaving clinical therapies.